CF
NRSN icon

Cantor Fitzgerald’s NeuroSense Therapeutics NRSN Stock Holding History

Cantor Fitzgerald’s Portfolio NRSN Stock Details NRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-79,492
Closed -$101K – 317
2024
Q3 		$101K Buy
+79,492
New +$75.6K ﹤0.01% 153

Other funds holding NRSN

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Cantor Fitzgerald's NRSN Position: Q4 2024 in Review

Cantor Fitzgerald sold out of NeuroSense Therapeutics (NRSN) in Q4 2024, closing a stake of 79,492 shares — an estimated $101K sold.

Cantor Fitzgerald first reported a position in NRSN in Q3 2024 and held it in 1 quarter. The position peaked at $101K in Q3 2024. 13 funds tracked by Wall St. Rank hold NRSN as of Q4 2024.

  • Cantor Fitzgerald reported no remaining NeuroSense Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Cantor Fitzgerald sold 79,492 NeuroSense Therapeutics shares in Q4 2024, an estimated $101K.
  • Cantor Fitzgerald first reported a position in NeuroSense Therapeutics in Q3 2024 and held it in 1 quarter.
  • Cantor Fitzgerald's NeuroSense Therapeutics position peaked at $101K in Q3 2024.
  • 13 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q4 2024.

Based on Cantor Fitzgerald's 13F filing for Q4 2024, filed 14 Feb 2025.